EQS-Adhoc: Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025
|
EQS-Ad-hoc: Biotest AG / Key word(s): Delisting
Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025 Dreieich, 03 June 2025. The Frankfurt Stock Exchange today informed Biotest AG that it has approved the company's application to revoke the admission of Biotest shares (ordinary shares of Biotest AG: ISIN°DE0005227201, Biotest AG preference shares: ISIN DE0005227235) from trading on the regulated market of the Frankfurt Stock Exchange and in the segment of the regulated market with additional post-admission requirements (Prime Standard). In accordance with the end of the acceptance period specified in the offer document for the public delisting offer by Grifols Biotest Holdings GmbH, the delisting will take effect at the end of 6 June 2025. After this date, the shares of Biotest AG will no longer be traded on the Frankfurt Stock Exchange and the additional listing requirements will no longer apply.
Biotest Aktiengesellschaft Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.com
Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,500 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been part of the Grifols Group, Barcelona, Spain (www.grifols.com).
IR contact Dr. Monika Baumann (Buttkereit) phone: +49-6103-801-4406
PR contact Dirk Neumüller phone: +49-6103-801-269
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard) Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate End of Inside Information
03-Jun-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Biotest AG |
| Landsteinerstraße 5 | |
| 63303 Dreieich | |
| Germany | |
| Phone: | 0 61 03 - 8 01-0 |
| E-mail: | ir@biotest.com |
| Internet: | www.biotest.com |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2149954 |
| End of Announcement | EQS News Service |
|
|
2149954 03-Jun-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 484,20 | 515,60 | 516,10 | 684,60 | 726,20 | 680,00 | 0,00 | |
| EBITDA1,2 | 28,30 | -16,10 | 19,20 | 179,40 | 135,10 | -24,00 | 0,00 | |
| EBITDA-Margin3 | 5,85 | -3,12 | 3,72 | 26,21 | 18,60 | -3,53 | 0,00 | |
| EBIT1,4 | -1,30 | -47,10 | -16,60 | 143,50 | 94,50 | -67,00 | 0,00 | |
| EBIT-Margin5 | -0,27 | -9,14 | -3,22 | 20,96 | 13,01 | -9,85 | 0,00 | |
| Net Profit (Loss)1 | -31,40 | -63,40 | -31,70 | 127,00 | 26,40 | -110,00 | 0,00 | |
| Net-Margin6 | -6,49 | -12,30 | -6,14 | 18,55 | 3,64 | -16,18 | 0,00 | |
| Cashflow1,7 | -16,70 | 33,90 | -40,50 | -2,70 | 60,90 | -125,00 | 0,00 | |
| Earnings per share8 | -0,72 | 1,59 | -0,79 | 3,22 | 0,68 | -2,75 | -1,30 | |
| Dividend per share8 | 0,04 | 0,04 | 0,00 | 0,08 | 0,04 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Biotest VZ | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 522723 | DE0005227235 | AG | 1.456,23 Mio € | 14.10.1987 | 9F2C2M4X+6R | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 54,00 | 19,69 | 2,74 | 216,00 | 2,42 | 21,05 | 2,01 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,08 | 0,04 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 02.07.2025 | 12.05.2025 | 04.08.2025 | 10.11.2025 | 28.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +1,94% | +5,91% | +2,53% | +9,09% | +213,65% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
